Roche buys rights for danoprevir from InterMune
BASEL, Switzerland Swiss drug maker Roche has bought the rights to an investigative treatment for hepatitis C, Roche said.
The company announced Thursday that it had purchased global development and commercialization rights to the drug RG7227/ITMN-191 (danoprevir) from InterMune for $175 million.
Roche said the drug had shown promise in preclinical and early clinical development. The two companies have been developing the drug since 2006.
Gestational diabetes test may predict Type 2 diabetes among women
TEL AVIV, Israel A new Tel Aviv University study found a test used to diagnose gestational diabetes in women could be a key indicator to diagnosing Type 2 diabetes.
The study — led by Gabriel Chodick of Tel Aviv University’s department of epidemiology and preventive medicine at the Sackler faculty of medicine — found that women who "failed" the glucose challenge test, a series of four blood tests conducted over a single four-hour period, have a higher chance of developing adult onset diabetes later in life. Chodick and colleagues collected data on more than 185,000 women in Israel who took the glucose challenge test, then acquired information from the nation’s health registry as to what percentage of these women contracted diabetes later in life.
Chodick noted that nearly half of the women who failed all four parts of the four-part tests, demonstrating an elevated blood sugar level, developed Type 2 diabetes within 10 years. Those who failed 3-of-the-4 tests had a 20% overall chance of developing the disease within the same period. "This is the first-ever study to show the long-term health of those who failed the glucose challenge test," Chodick said.
Gestational diabetes is developed among women while they are about 28 weeks pregnant or later, when the body is not able to make and use all the insulin it needs for pregnancy.
Jonathan Roberts named COO of CVS Caremark’s PBM business
WOONSOCKET, R.I. CVS Caremark has appointed Jonathan Roberts as COO of its pharmacy benefit management business. He currently is EVP Rx purchasing, pricing and network relations, and also now will assume the leadership of PBM operations, mail-service pharmacy and specialty pharmacy.
“Jon is the ideal candidate to fill this newly created role within the PBM,” stated Per Lofberg, president of pharmacy benefit management at CVS Caremark. “His broad base of pharmacy experience will further our mission to continually improve how we do business and look for ways to do it better, more efficiently and at a lower cost.”
Roberts joined CVS/pharmacy nearly 20 years ago and has served in a variety of leadership roles across the enterprise, including SVP store operations at CVS/pharmacy and CIO of CVS Caremark.
“Jon has spearheaded numerous initiatives over the years that have enhanced our delivery of pharmacy care,” added Tom Ryan, chairman and CEO of CVS Caremark. “I am confident that in this newly expanded role Jon will support our PBM growth strategy and overall longer-term success.”